Investigators will evaluate the safety, tolerability, and exploratory signs of efficacy, including neurofilament light chain and SOD1 protein.

Treatment with the vaccine did not improve progression-free survival in patients with HPV16-positive cervical and anogenital tumors.

Drugmakers and insurers are exploring different payment schemes for expensive, potentially curative treatments, particularly ones tied to patient response.

Certain members of MotivHealth's HSA-based insurance plans will have access to DecisionRx's medication therapy optimization program.

With A$45 million in funding, the group will focus on research developing safer therapies and clinical trial programs for pediatric cancer treatment.

Seven of 67 patients who received the cerebral adrenoleukodystrophy gene therapy developed blood cancer, though most cases ...

The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US ...

The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.

In a post hoc analysis within a prior Phase II study, the company found SP-624 improved symptoms in female patients with major depressive disorder.

Researchers will develop therapies for urea cycle disorders and create a platform to rapidly develop treatments for other rare genetic disorders.

The firm is evaluating leniolisib, which is already approved and sold under the brand name Joenja for APDS, in certain primary immunodeficiencies with immune dysregulation.

In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.